On this page
What each program costs in California
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 6 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 7 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 10 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 12 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 13 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 14 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 15 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 16 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 17 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the CalPERS health program cover GLP-1s for weight loss?
All CalPERS health plans cover GLP-1s for diabetes and certain obesity-related conditions such as sleep apnea. CalPERS HMO plans that run their own pharmacy benefit, including Blue Shield of California and Kaiser Permanente, also cover them for morbid obesity (BMI of 40 or higher) with prior authorization.
CalPERS Board of Administration
CalPERS's June 2026 Board item says every CalPERS plan covers GLP-1s for diabetes and certain obesity-related conditions.
“All CalPERS health plans currently cover GLP-1 medications for diabetes and certain obesity-related conditions, including obstructive sleep apnea, cardiovascular risk factors, and Metabolic Dysfunction-Associated Steatohepatitis.”
https://calpers.ca.gov/documents/202606-full-agenda-item8c-00-a/download?inline= · read Oct 29, 2026
CalPERS Board of Administration
Knox-Keene regulated CalPERS plans that manage their own pharmacy benefit cover GLP-1s for morbid obesity, with prior authorization.
“CalPERS’ Knox-Keene regulated plans that manage their own pharmacy benefit, including HMO plans offered by Blue Shield of California and Kaiser Permanente, cover GLP-1 medications for morbid obesity (BMI ≥ 40 kg/m2), subject to prior authorization requirements.”
https://calpers.ca.gov/documents/202606-full-agenda-item8c-00-a/download?inline= · read Oct 29, 2026
What do California's big insurers publish on Wegovy and Zepbound?
Health plans regulated under California's Knox-Keene Act
CalPERS states that California law requires Knox-Keene regulated health plans to cover GLP-1s for diabetes and for morbid obesity (BMI of 40 or higher).
Blue Shield of California
From January 1, 2025 or plan renewal, Blue Shield of California stopped covering weight loss medications for some commercial PPO and HMO members unless they are medically necessary for Class III (morbid) obesity, with a required weight loss program.
Blue Shield of California
Blue Shield of California's November 2024 fact sheet ends coverage of listed weight loss medications for some commercial members from January 1, 2025 or renewal, unless authorized as medically necessary.
“Beginning January 1, 2025, or upon an employer group’s or individual purchaser’s plan renewal after that date, the weight loss medications listed below will no longer be covered for some Blue Shield of California (Blue Shield) commercial PPO and HMO plan members unless authorization for medical necessity is provided by Blue Shield.”
https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/Weight-Loss-Drug-Exclusion-Fact-Sheet.pdf · read Oct 29, 2026
Blue Shield of California
Authorization for affected members requires a current or previous Class III obesity diagnosis.
“Blue Shield will authorize weight loss medications for members affected by the benefit change if the medication is determined to be medically necessary for the treatment of a current or previous diagnosis of Class III (morbid) obesity.”
https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/Weight-Loss-Drug-Exclusion-Fact-Sheet.pdf · read Oct 29, 2026
Does California Medicaid (Medi-Cal) cover GLP-1s for weight loss?
Not covered for weight loss
Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound or any other GLP-1 drug for weight loss, with medical-necessity review of weight-loss requests only for members under 21. Read from state documents Nov 6, 2026.
What California Medicaid (Medi-Cal)'s documents say about each drug for weight loss. Read Nov 6, 2026. California Department of Health Care Services.
WegovyNo
Covered for noncirrhotic MASH with a diagnosis code; prior authorization requests for uses such as cardiovascular disease are reviewed for medical necessity. Under age 21: weight-loss requests are reviewed for medical necessity under the federal EPSDT benefit.
“Effective January 1, 2026, Wegovy is no longer eligible for coverage for weight loss or weight loss-related indications.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
“Medi-Cal Rx no longer covers any GLP-1 drugs for weight loss or weight loss-related indications.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
ZepboundNo
Removed from the Contract Drugs List; prior authorization requests are considered for obstructive sleep apnea. Under age 21: weight-loss requests are reviewed for medical necessity under the federal EPSDT benefit.
“have been removed from the Medi-Cal Rx Contract Drugs List (CDL) and are no longer eligible for coverage for weight loss or weight loss-related indications”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
“PA requests for Zepbound will be considered when used for obstructive sleep apnea (OSA).”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
“Medi-Cal Rx no longer covers any GLP-1 drugs for weight loss or weight loss-related indications.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
OzempicNo
Covered for type 2 diabetes with a diagnosis code. Under age 21: weight-loss requests are reviewed for medical necessity under the federal EPSDT benefit.
“The following GLP-1 drugs are currently on the CDL and continue to have a Code I diagnosis restriction of type 2 diabetes.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
“Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, or Trulicity for type 2 diabetes”
California DHCS, Medi-Cal Rx · No effective date on the document · read Nov 6, 2026
“Medi-Cal Rx no longer covers any GLP-1 drugs for weight loss or weight loss-related indications.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
MounjaroNo
Covered for type 2 diabetes with a diagnosis code. Under age 21: weight-loss requests are reviewed for medical necessity under the federal EPSDT benefit.
“The following GLP-1 drugs are currently on the CDL and continue to have a Code I diagnosis restriction of type 2 diabetes.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
“Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, or Trulicity for type 2 diabetes”
California DHCS, Medi-Cal Rx · No effective date on the document · read Nov 6, 2026
“Medi-Cal Rx no longer covers any GLP-1 drugs for weight loss or weight loss-related indications.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from California Department of Health Care Services documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
- Apr 1, 2026 · Policy changeWegovy for noncirrhotic MASH no longer needs prior authorization.
“Effective April 1, 2026, Wegovy does not require an approved prior authorization (PA) when prescribed for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis”
California DHCS, Medi-Cal Rx · Effective Apr 1, 2026 · read Nov 6, 2026
- Jan 1, 2026 · Policy changeEnded coverage of GLP-1 drugs for weight loss; removed Zepbound from the Contract Drugs List.
“Effective January 1, 2026, Wegovy is no longer eligible for coverage for weight loss or weight loss-related indications.”
California DHCS, Medi-Cal Rx · Effective Jan 1, 2026 · read Nov 6, 2026
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
1,712,999 prescriptions
Ozempic and Mounjaro, 2025
1,148,619 prescriptions
Neighbours covering weight loss
0 of 3
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your California Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed California Medicaid as "not covered" for GLP-1s for obesity under fee-for-service. California covered GLP-1s for obesity in October 2025 and had ended that coverage by January 2026.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether California Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does California Medicaid pay for?
3.09 million GLP-1 prescriptions in 2025, 1st of the 50 states and DC, with $3.4 billion reimbursed before rebates. Counting the share other payers covered, $3.5 billion.
Prescriptions, 2025
3,089,327
1st of 51
Medicaid paid
$3.4B
1st of 51, before rebates
Per prescription
$1,103
$1,051 nationally
Weight-loss brands
55%
6th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. California is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 55% of California Medicaid's GLP-1 prescriptions in 2025 (1,712,999). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Wegovy was California Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Wegovyapproved for weight management | 1,000,304 | 32% | $1.3 billion | $1,303 |
| Ozempic | 915,084 | 30% | $863.2 million | $943 |
| Zepboundapproved for weight management | 701,827 | 23% | $735.5 million | $1,048 |
| Mounjaro | 233,535 | 7.6% | $241.1 million | $1,032 |
| Trulicity | 127,774 | 4.1% | $122.6 million | $960 |
| Rybelsus | 85,505 | 2.8% | $122.4 million | $1,432 |
| Saxendaapproved for weight management | 10,868 | 0.4% | $13.1 million | $1,209 |
| Liraglutide (generic) | 9,710 | 0.3% | $3.8 million | $396 |
| Victoza | 3,862 | 0.1% | $2.5 million | $638 |
| Bydureon | 816 | 0.0% | $664,801 | $815 |
| Byetta | 31 | 0.0% | $27,308 | $881 |
| Exenatide (generic) | 11 | 0.0% | $8,165 | $742 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in California?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 8 in California. The register does not say which, if any, supplies a program on this page.
- Hybrid Pharma, LLC, Deerfield Beach. Registered since Jan 14, 2015; last FDA inspection Aug 27, 2026.
- McGuff Pharmaceuticals, Inc. dba McGuff Outsourcing Solutions, Santa Ana. Registered since Jan 11, 2023; not yet inspected by FDA.
- MedisourceRx, Los Alamitos. Registered since Feb 14, 2017; last FDA inspection Jun 10, 2025.
- Nivagen Pharmaceuticals, LLC, Sacramento. Registered since Mar 13, 2026; not yet inspected by FDA.
- Nubratori, Inc., Torrance. Registered since Feb 24, 2017; last FDA inspection Dec 11, 2025.
- Vitae Enim Vitae Scientific, Inc., San Diego. Registered since Jan 2, 2024; not yet inspected by FDA.
- Wedgewood Connect, LLC, formerly registered as Leiter's Compounding, San Jose. Registered since Jan 31, 2014; last FDA inspection Jul 3, 2025.
- Xseer Pharmaceuticals, Inc., Los Angeles. Registered since Oct 21, 2023; not yet inspected by FDA.
On Medicare in California?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
California and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 3 states next to California covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than California's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| California | Not covered | 17 | $39/mo |
| Arizona | Not covered in part | 19 | $39/moWellmedr |
| Nevada | Not covered | 19 | $39/moWellmedr |
| Oregon | Not covered | 19 | $39/moWellmedr |




















